Alicia Grande - Aug 17, 2022 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
VP, Treasurer and CFO
Signature
/s/ Alicia Grande
Stock symbol
CPRX
Transactions as of
Aug 17, 2022
Transactions value $
-$1,695,983
Form type
4
Date filed
8/19/2022, 05:02 PM
Previous filing
Feb 16, 2022
Next filing
Aug 30, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $251K +99.3K +20.89% $2.53* 575K Aug 17, 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$1.38M -99.3K -17.28% $13.85 476K Aug 17, 2022 Direct F1, F3
transaction CPRX Common stock, par value $0.001 per share Options Exercise $79.5K +31.4K +6.61% $2.53* 507K Aug 17, 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$436K -31.4K -6.2% $13.87 476K Aug 17, 2022 Direct F2, F3
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $48.7K +19.3K +4.05% $2.53* 495K Aug 18, 2022 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale -$264K -19.3K -3.89% $13.70 476K Aug 18, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -99.3K -6.59% $0.00 1.41M Aug 17, 2022 Common Stock 99.3K $2.53 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -31.4K -2.23% $0.00 1.38M Aug 17, 2022 Common Stock 31.4K $2.53 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -19.3K -1.4% $0.00 1.36M Aug 18, 2022 Common Stock 19.3K $2.53 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold in various lots from $13.85 to $13.88 per share. The listed sale price represents a weighted average price for the shares sold.
F2 Shares were sold in various lots from $13.87 to $13.88 per share. The listed sale price represents a weighted average price for the shares sold.
F3 Shares were sold to cover exercise price of options, tax withholding requirements (if applicable) and for personal reasons. Shares were not sold as a result of any disagreement with the Company and Ms. Grande remains an officer of the Company.
F4 Options vested in three annual tranches beginning on December 30, 2016.